New NHS review calls for increase in uptake of lifesaving vaccines

25 October 2019

In light of the UK recently losing its ‘measles-free’ status with the World Health Organization (WHO) – just three years after the virus was eliminated in the country, largely due to the controversy over measles, mumps, meningitis/rubella (MMR) vaccination - today NHS England released a review that calls for more lifesaving vaccines to be provided in convenient locations of parents to drive uptake.

The analysis shows that one in seven children aged five had not had both doses of essential measles jabs.

Health leaders will also look at how payments to general practitioners (GPs) will ensure they vaccinate as many children and young people as possible against MMR.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK